巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    OptiNose

    OPTN
    3.735
    0.090
    2.33%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・OptiNose - 延遲價格・最後更新於 05/07 7:25
    最高位
    3.750
    最低位
    3.610
    開市價
    --
    前收市價
    3.650
    成交量(千)
    2.15
    成交額(百萬)
    0.08
    買入
    3.700
    賣出
    3.740
    每手股數
    --
    市值(百萬)
    308.81
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.970 - 1.455
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    OptiNose
    證券代碼
    OPTN.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation delivery system, to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825.
    發行量
    82418106
    公司總部
    1020 Stony Hill Road, Suite 300
    公司網址
    https://www.optinose.com
    公司電郵
    investors@optinose.com
    公司電話
    +1 267 364-3500
    暫無內容

    關於

    OptiNose(OPTN.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    OptiNose Inc is a US-based specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, utilizes a proprietary breath powered exhalation delivery system, to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids. The pipeline products of the company include XHANCE, OPN-300, OPN-021, and AVP-825.
    詳細公司背景可參考: https://www.optinose.com